|
시장보고서
상품코드
1991508
마이코플라스마 검사 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)Global Mycoplasma Testing Market Size, Share, Trends & Growth Analysis Report 2026-2034 |
||||||
마이코플라스마 검사 시장 규모는 2025년 12억 6,466만 달러에서 2034년에는 41억 8,459만 달러에 달할 것으로 예측되며, 2026년부터 2034년까지 CAGR 14.22%로 성장할 것으로 전망됩니다.
생명공학 및 제약 산업이 제품 안전과 품질 보장에 집중함에 따라 세계 마이코플라스마 검사 시장이 확대되고 있습니다. 마이코플라스마는 생물학적 연구나 의약품 제조에 사용되는 세포 배양을 오염시킬 수 있는 미세한 박테리아다. 연구 결과의 신뢰성을 훼손하거나 안전성에 문제가 있는 의료제품이 생산되는 것을 방지하기 위해 실험실 및 제조 시설에서 마이코플라스마 오염 검사는 필수적입니다.
시장 성장은 바이오의약품 생산 증가와 제품 안전에 대한 규제 요건 강화에 힘입어 성장하고 있습니다. 제약회사와 연구기관은 오염을 신속하고 정확하게 검출하기 위해 첨단 검사 기술에 의존하고 있습니다. 분자진단법의 발전으로 검사의 효율성과 민감도가 향상되었습니다.
생명공학의 연구개발이 계속 확대되면서 마이코플라스마 검사 시장의 향후 전망은 여전히 밝습니다. 자동 검사 시스템 및 신속한 검출 방법의 혁신으로 실험실 생산성을 향상시킬 수 있습니다. 또한, 세포 치료 및 백신 개발에 대한 투자 증가도 신뢰할 수 있는 오염 검사 기술에 대한 수요를 견인할 것으로 예상됩니다.
목차
제1장 소개
제2장 주요 요약
제3장 시장 변수, 동향, 프레임워크
제4장 세계의 마이코플라스마 검사 시장 : 제품별
제5장 세계의 마이코플라스마 검사 시장 : 기술별
제6장 세계의 마이코플라스마 검사 시장 : 용도별
제7장 세계의 마이코플라스마 검사 시장 : 최종사용별
제8장 세계의 마이코플라스마 검사 시장 : 지역별
제9장 경쟁 구도
제10장 기업 개요
KSM 26.04.14The Mycoplasma Testing Market size is expected to reach USD 4184.59 Million in 2034 from USD 1264.66 Million (2025) growing at a CAGR of 14.22% during 2026-2034.
The global mycoplasma testing market has expanded as biotechnology and pharmaceutical industries focus on ensuring product safety and quality. Mycoplasma are small bacteria that can contaminate cell cultures used in biological research and drug production. Testing for mycoplasma contamination is essential in laboratories and manufacturing facilities to prevent compromised research results and unsafe medical products.
Market growth is driven by increasing biopharmaceutical production and stricter regulatory requirements for product safety. Pharmaceutical companies and research institutions rely on advanced testing technologies to detect contamination quickly and accurately. Improvements in molecular diagnostic methods have enhanced testing efficiency and sensitivity.
The future outlook for the mycoplasma testing market remains positive as biotechnology research continues to expand. Innovations in automated testing systems and rapid detection methods may improve laboratory productivity. Increasing investments in cell-based therapies and vaccine development are also expected to drive demand for reliable contamination testing technologies.
MARKET SEGMENTATION
By Product
- Instruments
- Kits & Reagents
- Services
By Technology
- PCR
- ELISA
- Direct Assay
- Indirect Assay
- Microbial Culture Techniques
- Enzymatic Methods
By Application
- Cell Line Testing
- Virus Testing
- End of Production Cells Testing
- Others
By End-use
- Academic Research Institutes
- Cell Banks
- Contract Research Organizations
- Pharmaceutical & Biotechnology Companies
- Others
COMPANIES PROFILED
- Thermo Fisher Scientific Inc, Lonza Group AG, Merck KGaA, Charles River Laboratories International Inc, PromoCell GmbH, American Type Culture Collection, Asahi Kasei Medical Co Ltd, Sartorius AG, InvivoGen, Eurofins Scientific, ATCC American Type Culture Collection
- We can customise the report as per your requirements.
TABLE OF CONTENTS
Chapter 1. PREFACE
- 1.1. Market Segmentation & Scope
- 1.2. Market Definition
- 1.3. Information Procurement
- 1.3.1 Information Analysis
- 1.3.2 Market Formulation & Data Visualization
- 1.3.3 Data Validation & Publishing
- 1.4. Research Scope and Assumptions
- 1.4.1 List of Data Sources
Chapter 2. EXECUTIVE SUMMARY
- 2.1. Market Snapshot
- 2.2. Segmental Outlook
- 2.3. Competitive Outlook
Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK
- 3.1. Market Lineage Outlook
- 3.2. Penetration & Growth Prospect Mapping
- 3.3. Value Chain Analysis
- 3.4. Regulatory Framework
- 3.4.1 Standards & Compliance
- 3.4.2 Regulatory Impact Analysis
- 3.5. Market Dynamics
- 3.5.1 Market Drivers
- 3.5.2 Market Restraints
- 3.5.3 Market Opportunities
- 3.5.4 Market Challenges
- 3.6. Porter's Five Forces Analysis
- 3.7. PESTLE Analysis
Chapter 4. GLOBAL MYCOPLASMA TESTING MARKET: BY PRODUCT 2022-2034 (USD MN)
- 4.1. Market Analysis, Insights and Forecast Product
- 4.2. Instruments Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 4.3. Kits & Reagents Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 4.4. Services Estimates and Forecasts By Regions 2022-2034 (USD MN)
Chapter 5. GLOBAL MYCOPLASMA TESTING MARKET: BY TECHNOLOGY 2022-2034 (USD MN)
- 5.1. Market Analysis, Insights and Forecast Technology
- 5.2. PCR Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 5.3. ELISA Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 5.4. Direct Assay Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 5.5. Indirect Assay Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 5.6. Microbial Culture Techniques Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 5.7. Enzymatic Methods Estimates and Forecasts By Regions 2022-2034 (USD MN)
Chapter 6. GLOBAL MYCOPLASMA TESTING MARKET: BY APPLICATION 2022-2034 (USD MN)
- 6.1. Market Analysis, Insights and Forecast Application
- 6.2. Cell Line Testing Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 6.3. Virus Testing Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 6.4. End of Production Cells Testing Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 6.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)
Chapter 7. GLOBAL MYCOPLASMA TESTING MARKET: BY END-USE 2022-2034 (USD MN)
- 7.1. Market Analysis, Insights and Forecast End-use
- 7.2. Academic Research Institutes Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 7.3. Cell Banks Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 7.4. Contract Research Organizations Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 7.5. Pharmaceutical & Biotechnology Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
- 7.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)
Chapter 8. GLOBAL MYCOPLASMA TESTING MARKET: BY REGION 2022-2034 (USD MN)
- 8.1. Regional Outlook
- 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 8.2.1 By Product
- 8.2.2 By Technology
- 8.2.3 By Application
- 8.2.4 By End-use
- 8.2.5 United States
- 8.2.6 Canada
- 8.2.7 Mexico
- 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 8.3.1 By Product
- 8.3.2 By Technology
- 8.3.3 By Application
- 8.3.4 By End-use
- 8.3.5 United Kingdom
- 8.3.6 France
- 8.3.7 Germany
- 8.3.8 Italy
- 8.3.9 Russia
- 8.3.10 Rest Of Europe
- 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 8.4.1 By Product
- 8.4.2 By Technology
- 8.4.3 By Application
- 8.4.4 By End-use
- 8.4.5 India
- 8.4.6 Japan
- 8.4.7 South Korea
- 8.4.8 Australia
- 8.4.9 South East Asia
- 8.4.10 Rest Of Asia Pacific
- 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 8.5.1 By Product
- 8.5.2 By Technology
- 8.5.3 By Application
- 8.5.4 By End-use
- 8.5.5 Brazil
- 8.5.6 Argentina
- 8.5.7 Peru
- 8.5.8 Chile
- 8.5.9 Rest of Latin America
- 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 8.6.1 By Product
- 8.6.2 By Technology
- 8.6.3 By Application
- 8.6.4 By End-use
- 8.6.5 Saudi Arabia
- 8.6.6 UAE
- 8.6.7 Israel
- 8.6.8 South Africa
- 8.6.9 Rest of the Middle East And Africa
Chapter 9. COMPETITIVE LANDSCAPE
- 9.1. Recent Developments
- 9.2. Company Categorization
- 9.3. Supply Chain & Channel Partners (based on availability)
- 9.4. Market Share & Positioning Analysis (based on availability)
- 9.5. Vendor Landscape (based on availability)
- 9.6. Strategy Mapping
Chapter 10. COMPANY PROFILES OF GLOBAL MYCOPLASMA TESTING INDUSTRY
- 10.1. Top Companies Market Share Analysis
- 10.2. Company Profiles
- 10.2.1 Thermo Fisher Scientific Inc
- 10.2.2 Lonza Group AG
- 10.2.3 Merck KGaA
- 10.2.4 Charles River Laboratories International Inc
- 10.2.5 PromoCell GmbH
- 10.2.6 American Type Culture Collection
- 10.2.7 Asahi Kasei Medical Co. Ltd
- 10.2.8 Sartorius AG
- 10.2.9 InvivoGen
- 10.2.10 Eurofins Scientific
- 10.2.11 (ATCC) American Type Culture Collection
